ARTICLE SUMMARY:
Now that renal denervation is FDA-approved, Medicare-covered, and guideline-recommended, Medtronic is investing in additional research to show it does more than just reduce blood pressure.
After decades of research and investment, renal denervation (RDN)—ablating the nerves around the renal artery that regulate blood flow—is finally established as a widely available option for patients with uncontrolled hypertension.
